Custom cover image
Custom cover image

Targeted Interference with Signal Transduction Events / edited by Bernd Groner

Contributor(s): Resource type: Ressourcentyp: Buch (Online)Book (Online)Language: English Series: Resent Results in Cancer Research ; 172 | SpringerLink BücherPublisher: Berlin, Heidelberg : Springer-Verlag Berlin Heidelberg, 2007Description: Online-Ressource (IX, 188 p, online resource)ISBN:
  • 9783540312093
Subject(s): Genre/Form: Additional physical formats: 9783540312086 | Erscheint auch als: Targeted interference with signal transduction events. Druck-Ausgabe. Berlin : Springer, 2007. IX, 188 S.DDC classification:
  • 614.5999
  • 616.994061
  • 610
RVK: RVK: XH 4900LOC classification:
  • RC261-271
  • RC271.C5
DOI: DOI: 10.1007/978-3-540-31209-3Online resources: Summary: This book does nothing less than lay out the state of development of tomorrow's cancer drugs, directed against growth factors, growth factor receptors and intracellular signaling molecules with kinase activities. The sequencing of the human genome and insights into signaling pathways have contributed to the understanding of cancer etiology and the development of new, improved cancer drugs such as Herceptin and Glivec. The deregulation of pathways due to mutated cancer genes provides the conceptual basis for future progress. Will it be possible to derive more efficient cancer drugs?Summary: Sequencing of the human genome and insights into signaling pathways have contributed to the understanding of cancer etiology and the development of new, improved cancer drugs. DNA mutations of a limited set of genes are responsible for the multiple stages of tumorigenesis and metastasis. Matching of therapeutic intervention with insights into the underlying molecular disease mechanism has led to the development of drugs such as Herceptin and Glivec. The deregulation of pathways due to mutated cancer genes provides the conceptual basis for future progress. Will it be possible to extrapolate this principle and derive more efficient drugs targeting cancer pathway components? Potential drug targets have been identified, but our ability to predict the consequences of inhibition of such components is still limited. The state of development of tomorrow’s cancer drugs, directed against growth factors, growth factor receptors and intracellular signaling molecules with kinase activities, is described in this book.PPN: PPN: 1647121698Package identifier: Produktsigel: ZDB-1-SMI | ZDB-2-SME | ZDB-2-SBL
No physical items for this record
KIT – The University in the Helmholtz Association                         Home | Impressum | Datenschutz | Barrierefreiheit | KIT